DESONIDE SUMMARY
Desonide Ointment, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11β,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents.
Desonide Ointment, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.
It should not be used for longer than two weeks unless directed by a physician.
|
|
NEWS HIGHLIGHTS
Published Studies Related to Desonide (Desonide Topical)
An investigator-blind, randomized, 4-week, parallel-group, multicenter pilot study to compare the safety and efficacy of a nonsteroidal cream (Promiseb Topical Cream) and desonide cream 0.05% in the twice-daily treatment of mild to moderate seborrheic dermatitis of the face. [2009.11] The treatment of seborrheic dermatitis includes topical antifungal agents to eradicate Malassezia spp, corticosteroids, which treat the inflammatory component of the disease and keratolytics which remove scale and crust. This study compared the efficacy of a nonsteroidal topical cream and a low-potency topical corticosteroid for the treatment of mild to moderate seborrheic dermatitis of the face in 77 volunteers randomized to twice-daily treatment with nonsteroidal cream or corticosteroid cream for up to 28 days...
Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. [2007.02] Low to mid potency corticosteroids remain a cornerstone of therapy for atopic dermatitis (AD)...
Corneofungimetry bioassay on Malassezia spp. under ketoconazole and desonide influences. [2005.03] CONCLUSION: The presence of 0.05% desonide does not impair or improve the Malassezia susceptibility to 2% ketoconazole when growing on lipid-enriched human stratum corneum. Copyright 2005 S. Karger AG, Basel.
Self-reported participant experience with desonide hydrogel in the treatment of mild to moderate atopic dermatitis. [2011.07] The objective of this study was to evaluate patients' real-world experiences with desonide hydrogel for the treatment of mild to moderate atopic dermatitis (AD). Physicians who participated in this patient-experience program identified eligible participants (age range, < 3 months to 91 years) for treatment with desonide hydrogel 0.05%...
Good adherence and early efficacy using desonide hydrogel for atopic dermatitis: results from a program addressing patient compliance. [2010.04] BACKGROUND: Patients with atopic dermatitis (AD) may have poor adherence for several reasons, including fear of side effects or dislike of messy topical therapies. PURPOSE: To assess adherence to and efficacy of a multifaceted program for atopic dermatitis using a lightweight, easy-to-apply medication and more frequent return visits... CONCLUSION: Subjects responded very well to treatment, and adherence to desonide hydrogel 0.05% was much better than previously reported with ointments. The early efficacy, favorable attributes of the hydrogel vehicle and judicious follow up likely increased adherence to topical therapy. The use of ointments or more potent topical steroids as a first choice may be counterproductive in the treatment of atopic dermatitis.
Clinical Trials Related to Desonide (Desonide Topical)
Skin Effects of a Topical Amino Acid Moisturizing Cream and Desonide in Atopic Dermatitis [Recruiting]
The purpose of this study is to compare the effects of an amino acid moisturizing cream and
desonide cream in reducing skin symptoms associated with AD/eczema in subjects with mild to
moderate atopic dermatitis/eczema.
Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation [Completed]
Axillary hyperpigmentation is a frequent consultation in dark skin populations although its
exact prevalency is unknown. Currently, there are not studies about physiopathology and
treatment for this entity. The objective is to evaluate the depigmenting effect of topical
4% niacinamide versus 0. 05% desonide in axillary hyperpigmentation.
At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50
years are going to be randomly assigned to receive niacinamide, desonide or placebo daily.
No hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9
weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as
Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.
Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis [Completed]
The purpose of this research study is to better understand how this study drug works when
people use it to treat atopic dermatitis. Desonate has been approved by the US Food and
Drug Administration (FDA) for atopic dermatitis.
Comparison of the Efficacy and Safety of Two Topical Creams for Pediatric Atopic Dermatitis [Completed]
This study compares the effectiveness of two topical creams for atopic dermatitis in
pediatric subjects. Subjects will be randomly assigned to use one of the two creams twice
daily for 6 weeks or until clear.
Efficacy Emollient on Xerosis in Children With Atopic Dermatitis [Completed]
Atopic dermatitis is a frequent, chronic inflammatory disease influenced by local,
immunological, genetic and environmental factors. Important symptoms of atopic dermatitis
are dry skin, intense pruritus and impaired epidermal barrier function. Atopic dermatitis is
associated with skin barrier dysfunction that facilitates an easier allergen penetration
into the skin with an increased irritation and subsequent cutaneous inflammation. A lack of
important stratum corneum intercellular lipids and an inadequate ratio between compounds
enhance trans-epidermal water loss leading to xerosis. Skin hydration by emollient therapy
usually twice daily improves dryness and subsequently pruritus during the treatment of
atopic dermatitis and especially improves the barrier function. Emollients make part of
basic therapy (grade 1) for treatment of atopic dermatitis (European Academy of Dermatology
and Venereology Task Force 2009 Position Paper). Improvement of cutaneous barrier
alteration, measured by skin hydration, is a key element for evaluation of emollient
treatment efficacy.
The primary objective of this study is to demonstrate the efficacy of the tested product
(V0034CR01B) cream on xerosis in children with atopic dermatitis compared to the excipient
formula during 28 days.
|
PATIENT REVIEWS / RATINGS / COMMENTSBased on a total of 1 ratings/reviews, Desonide has an overall score of 4. The effectiveness score is 6 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
| Desonide review by 29 year old female patient | | Rating |
Overall rating: | | |
Effectiveness: | | Moderately Effective |
Side effects: | | Moderate Side Effects | | Treatment Info |
Condition / reason: | | exzema of the face |
Dosage & duration: | | 0.05% (dosage frequency: up to three times daily) for the period of up to 6 months |
Other conditions: | | none. just skin irritations |
Other drugs taken: | | none | | Reported Results |
Benefits: | | the treatment benefits was that the skin irritation did go away for awhile. I thought that I had been cured of the skin rash. It cleared my skin up and gave me relief from the rash. |
Side effects: | | It turns out it did not cure it at all but possibly hurt my face. It also may have made the condition spread to other areas of my face because in time I had other areas of my face where the rash was. The cream was only a temporary relief to a deeper situation. If one is looking for fast relief it will help but it covers up an initial problem that needs to be addressed. |
Comments: | | I saw a few dermatologists and each one told me to use it twice daily. I was even given different forms. One a cream and the other a foam. I was also informed to use them for two weeks and then stop. I did, and when I stopped my rash slowly started coming back. |
|
|
Page last updated: 2011-12-09
|